论文部分内容阅读
乙肝肝硬化即使经积极保肝治疗,病情仍会反复,使用保肝药物时病情减轻,减药及停药后病情加重,导致病情迁延不愈。由代偿期肝硬化发展到失代偿期肝硬化,甚至发生肝功能衰竭。研究表明,乙型肝炎肝硬化患者均存在不同程度的HBV复制,而抑制病毒复制是控制病情的关键[1]。为了观察核苷类药物治疗乙型肝炎肝硬化疗效,我们从2012年1月—2015年1月,对部分在乙型肝炎肝硬化患者应用核苷类药物治疗,并对其疗效
Hepatitis B cirrhosis even after active treatment of liver, the disease will continue to be repeated, the use of liver protection drugs to reduce the severity of the reduction after drug withdrawal and withdrawal, aggravating the disease delay. From decompensated cirrhosis to decompensated cirrhosis, and even liver failure. Studies have shown that patients with hepatitis B cirrhosis have varying degrees of HBV replication, and inhibition of viral replication is the key to controlling the disease [1]. In order to observe the effect of nucleoside drugs on the treatment of hepatitis B cirrhosis, from January 2012 to January 2015, we applied nucleoside drugs to part of patients with hepatitis B cirrhosis and evaluated its curative effect